Investment report on MIPI

Apr 15 2010

StockPreacher.com announces an investment report featuring Molecular Insight Pharmaceuticals Inc. (Nasdaq:MIPI). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

Molecular Insight Pharmaceuticals Inc. (MIPI), a clinical-stage biopharmaceutical company, engages in the discovery, development and commercialization of targeted therapeutic and imaging radiopharmaceuticals for use in oncology. The Company has five clinical-stage candidates in development. Its lead oncology product candidates include Azedra, Onalta, Trofex and Solazed. Azedra and Onalta are being developed for the treatment of neuroendocrine cancers; Trofex is being developed for the detection of metastatic prostate cancer, and Solazed is being developed for the treatment of metastatic melanoma. Its non-oncology product candidate, Zemiva, is being developed for the diagnosis of cardiac ischemia (insufficient blood flow to the heart muscle).

Message Board Search for MIPI: http://www.boardcentral.com/boards/MIPI

In the report, the analyst notes:

"MIPI has created a rapidly advancing pipeline of therapeutic radiopharmaceuticals and targeted molecular imaging agents through internal discovery efforts and select in-licensing transactions with a focus on unmet medical needs in oncology and cardiology. The pipeline consists of targeted radiotherapeutics for the treatment of cancer and molecular imaging radiopharmaceuticals for the detection and monitoring of serious diseases, such as myocardial ischemia and cancer.

"MIPI recently announced results from the Phase 2 clinical trial of Onalta (Yttrium-90 edotreotide) showed that the cancer drug improved symptoms associated with metastatic carcinoid tumors ... 90Y-edotreotide treatment was well-tolerated with an acceptable expected adverse effect profile. It's clear from this study that symptoms associated with malignant carcinoid tumors improve following this therapy among patients with no treatment alternatives."

To read the entire report visit: http://www.stockpreacher.com/n/MIPI

Source StockPreacher.com